Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE E IN PLASTIC CONTAINER vs SODIUM PHENYLACETATE AND SODIUM BENZOATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.
Sodium phenylacetate and sodium benzoate provide an alternative pathway for nitrogen excretion in patients with urea cycle disorders. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is renally excreted, thereby eliminating waste nitrogen. Benzoate conjugates with glycine to form hippurate, which is also excreted in urine, removing ammonia precursors.
Maintenance of fluid and electrolyte balance in patients unable to take oral intake,Correction of metabolic acidosis when bicarbonate is contraindicated or not available,Replacement of electrolytes in hypokalemia, hyponatremia, hypomagnesemia, and hypocalcemia
Adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with urea cycle disorders (UCDs) involving deficiencies of carbamyl phosphate synthetase (CPS), ornithine transcarbamoylase (OTC), argininosuccinic acid synthetase (AS), argininosuccinic acid lyase (AL), or arginase (ARG). Also used for maintenance therapy in chronic management of UCDs.
Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.
Intravenous: Loading dose of 5.5 g/m² over 90-120 minutes, then continuous infusion of 5.5 g/m² over 24 hours.
Not applicable as a single agent; components have variable half-lives (e.g., sodium and chloride distribute rapidly with an elimination half-life of 2-4 hours depending on renal function). In renal impairment, half-life may be prolonged.
The terminal elimination half-life of phenylacetate is approximately 0.5-0.8 hours; however, its active conjugate phenylacetylglutamine has a half-life of about 1.2-1.5 hours. For benzoate, the half-life is approximately 0.5-1 hour. In the context of hyperammonemia treatment, the clinical effect correlates with the rapid formation of conjugates, and the half-life reflects quick clearance. In neonates or patients with renal impairment, half-life may be prolonged.
Acetate and gluconate are metabolized in the liver via the tricarboxylic acid cycle to bicarbonate; electrolytes are distributed in body fluids and excreted renally.
Sodium phenylacetate is metabolized via conjugation with glutamine to form phenylacetylglutamine. Sodium benzoate is metabolized via conjugation with glycine to form hippurate. Both metabolites are rapidly excreted by the kidneys.
Renal: >95% of administered electrolytes and water are excreted unchanged by the kidneys, primarily as urine. Biliary/fecal: <5% eliminated via feces, mainly unabsorbed components.
Sodium phenylacetate and sodium benzoate are primarily excreted renally. Phenylacetate is conjugated with glutamine to form phenylacetylglutamine, which is rapidly eliminated in urine. Benzoate is conjugated with glycine to form hippurate, also renally eliminated. Approximately 80-100% of the administered dose is recovered in urine as conjugates and minor metabolites. Fecal excretion is negligible (<5%).
Minimal to none: electrolytes like sodium, potassium, chloride, and bicarbonate are not protein-bound (<1%). Magnesium and calcium may have 30-50% binding to albumin, but overall negligible in solution.
Phenylacetate and benzoate are highly protein bound, primarily to albumin. Protein binding is approximately 80-90% for phenylacetate and 75-85% for benzoate. Binding may be saturable at high concentrations.
Distributes primarily into extracellular fluid (ECF) with Vd approximately 0.2 L/kg for sodium and chloride; calcium and magnesium distribute into a larger volume (0.5-0.6 L/kg) due to intracellular uptake.
The apparent volume of distribution for both drugs is small, approximately 0.2-0.3 L/kg, indicating limited extravascular distribution. This is consistent with their high protein binding and confinement to the vascular and interstitial spaces.
Intravenous: 100% (complete systemic availability). Not administered orally or by other routes for systemic effect.
Oral bioavailability is high, approximately 80-90% for both components, as they are well absorbed. However, for acute hyperammonemia, intravenous administration is preferred to ensure rapid and complete delivery.
Contraindicated in patients with severe renal impairment (GFR < 30 m L/min) due to risk of hyperkalemia. For GFR 30-50 m L/min, reduce infusion rate by 50% and monitor serum potassium closely. No adjustment needed for GFR > 50 m L/min.
Contraindicated if e GFR < 30 m L/min/1.73 m². For e GFR 30-50: reduce dose by 50% and monitor ammonia levels.
Child-Pugh Class A: no adjustment. Class B: reduce infusion rate by 25% and monitor serum potassium. Class C: use with caution; consider alternative solutions due to risk of electrolyte imbalance.
No specific adjustment; use with caution in severe hepatic impairment due to potential for increased ammonia.
Weight-based dosing: 20-30 m L/kg as a single intravenous infusion, administered at a rate not exceeding 5 m L/kg/hour. Maximum total volume: 1000 m L. Adjust based on clinical status and serum electrolytes.
Same weight-based dosing as adults: 5.5 g/m² IV loading then 5.5 g/m²/24h continuous infusion.
Elderly patients may require reduced infusion rates (2-5 m L/min) due to decreased renal function and higher risk of fluid overload. Monitor serum potassium and renal function closely.
No specific adjustment; monitor renal function and consider reduced dosing based on creatinine clearance.
None
WARNING: Contains sodium (approximately 30.2 mg/m L from sodium phenylacetate and sodium benzoate). Use caution in patients with congestive heart failure, severe renal insufficiency, or conditions with sodium retention. Additionally, neurotoxicity has been associated with phenylacetate accumulation; monitor plasma levels.
Monitor serum electrolytes, fluid balance, and renal function regularly. Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hypervolemia. Avoid rapid infusion; extravasation may cause tissue damage. Contains aluminum, which may accumulate in renal impairment.
Monitor ammonia levels, electrolytes, and neurological status. Risk of hypernatremia due to sodium content. Phenylacetate may cause neurotoxicity (tremors, agitation, coma) at high concentrations. Use with caution in patients with hepatic or renal impairment. Not recommended for patients with known hypersensitivity to phenylacetate or benzoate. Extravasation risk: avoid extravasation; if occurs, treat locally.
Hyperkalemia, hypernatremia, hypercalcemia, hypermagnesemia, severe metabolic alkalosis, severe renal failure with oliguria or anuria, and patients with a known hypersensitivity to any component.
Known hypersensitivity to sodium phenylacetate, sodium benzoate, or any component of the formulation; pre-existing severe hypernatremia (serum sodium >150 m Eq/L); neonates with hyperbilirubinemia (risk of kernicterus due to benzoate displacing bilirubin from albumin).
No direct food interactions; however, patients should avoid high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia is a concern. Monitor dietary sodium and fluid intake as per clinical status.
Administer with food or enteral feeding to reduce gastrointestinal irritation. Avoid high-protein meals during treatment as they may increase ammonia production. No specific food-drug interactions; restrict dietary protein as part of urea cycle disorder management (typically 0.5-2 g/kg/day).
ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid administration may cause maternal fluid and electrolyte disturbances that can indirectly affect the fetus. Use with caution in the setting of impaired uteroplacental perfusion.
FDA Pregnancy Category C. Animal studies with sodium phenylacetate and sodium benzoate at doses equivalent to human therapeutic exposure have shown teratogenic effects (skeletal and visceral malformations) when administered during organogenesis. Human data are insufficient to determine fetal risk. In the first trimester, potential for teratogenicity exists; use only if maternal benefit outweighs risk. Second and third trimester exposure may be associated with neonatal metabolic alkalosis, hypernatremia, and potential for kernicterus due to displacement of bilirubin from albumin. Avoid use during labor and delivery due to risk of neonatal hyperbilirubinemia.
ISOLYTE E is compatible with breastfeeding. Electrolytes are normally present in breast milk; exogenous administration does not significantly alter infant exposure. M/P ratio not applicable as drug is not a xenobiotic.
Excretion into human breast milk is unknown. The molecular weight of both sodium phenylacetate and sodium benzoate suggests potential for transfer into breast milk. The Milk-to-Plasma ratio is not established. Because of potential for serious adverse reactions in nursing infants (e.g., metabolic acidosis, neurotoxicity), breastfeeding is not recommended during therapy. Alternative feeding methods should be considered.
No dose adjustment is required for pregnancy. However, pregnant patients may have increased plasma volume and altered renal function; infusion rates should be individualized based on clinical status and serum electrolyte monitoring. Rapid correction of electrolyte imbalances should be avoided to prevent fetal osmotic shifts.
Pregnancy-induced hemodilution and increased renal clearance may require dose adjustments to maintain therapeutic ammonia levels. Monitor serum ammonia closely; consider starting at lower doses and titrating based on response. Due to increased plasma volume, distribution volume changes, and enhanced renal excretion, dose adjustments upward may be necessary. However, avoid excessive dosing to prevent maternal metabolic alkalosis or hypernatremia. Individualize therapy based on frequent ammonia monitoring, with consideration of gestational age. Postpartum, dose may need to be reduced as renal function normalizes.
ISOLYTE E is a balanced electrolyte solution with 5% dextrose, used for maintenance fluid therapy. Monitor serum potassium closely in renal impairment; contains 20 m Eq/L potassium. Caution in patients with hyperkalemia, renal failure, or metabolic alkalosis. Do not administer simultaneously with blood products due to risk of hemolysis. Observe for signs of fluid overload in patients with heart failure.
Administer intravenously via central line due to hypertonicity (p H 9-9.5). Monitor serum ammonia, potassium, and bicarbonate closely; hypokalemia and metabolic alkalosis are common. Use with caution in renal impairment (dose adjust for GFR <30 m L/min). Discontinue if hypernatremia or volume overload occurs. Caloric content: 2.5 kcal/m L from phenylacetate and benzoate.
This solution is used to replace fluids and electrolytes and provide calories. Tell your doctor if you have kidney problems, heart disease, or are on a low-potassium diet. Report any swelling, shortness of breath, or irregular heartbeat. Do not take over-the-counter potassium supplements without consulting your doctor.
This medication is used to remove excess ammonia from your blood due to a urea cycle disorder.,It is given through a central intravenous line; report any pain, redness, or swelling at the infusion site.,You may experience nausea, vomiting, or headache; notify your healthcare provider if severe.,Regular blood tests are necessary to monitor your ammonia levels and electrolytes.,Avoid taking other medications without consulting your doctor, as they may affect ammonia levels.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE E IN PLASTIC CONTAINER vs SODIUM PHENYLACETATE AND SODIUM BENZOATE, answered by our medical review team.
ISOLYTE E IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.. SODIUM PHENYLACETATE AND SODIUM BENZOATE is a Ammonia Detoxicant that works by Sodium phenylacetate and sodium benzoate provide an alternative pathway for nitrogen excretion in patients with urea cycle disorders. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is renally excreted, thereby eliminating waste nitrogen. Benzoate conjugates with glycine to form hippurate, which is also excreted in urine, removing ammonia precursors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE E IN PLASTIC CONTAINER and SODIUM PHENYLACETATE AND SODIUM BENZOATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE E IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.. The standard adult dose of SODIUM PHENYLACETATE AND SODIUM BENZOATE is: Intravenous: Loading dose of 5.5 g/m² over 90-120 minutes, then continuous infusion of 5.5 g/m² over 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE E IN PLASTIC CONTAINER and SODIUM PHENYLACETATE AND SODIUM BENZOATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE E IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid ad. SODIUM PHENYLACETATE AND SODIUM BENZOATE is classified as Category C. FDA Pregnancy Category C. Animal studies with sodium phenylacetate and sodium benzoate at doses equivalent to human therapeutic exposure have shown teratogenic effects (skeletal an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.